Welcome to factory-direct-buy
Hubei Yuancheng Saichuang Technology Co., Ltd
Hubei Yuancheng Saichuang Technology Co., Ltd
Sign in or Join Free Now!

Manufacturer Video

Contact Us

Street Address
496 Zhongshan Road
Country/Region
China (Mainland)/Hubei
Telephone

86-027-88215853

Pentadecapeptide Bpc 157 Human Growths Hormones Supplements Peptide CAS 137525-51-0 for Bodybuilding
Pentadecapeptide Bpc 157 Human Growths Hormones Supplements Peptide CAS 137525-51-0 for Bodybuilding
Supply Ability:
0 Gram/Grams per 0
Port:
Negotiable
Email:
Quantity:
Gram
  • Product Detils
  • Company Profile
Quick Details
Place of Origin:
China (Mainland)
Brand Name:
Pharmlab
Model Number:
137525-51-0
Packaging & Delivery
Disguised package; Foil bag
Product Description


Pentadecapeptide Bpc 157 Human Growths Hormones Supplements Peptide CAS 137525-51-0 for Bodybuilding 


Basic Info

 

Alias : Booly Protection Compound 15, Pentadecapeptide, BPC 157

CAS : 137525-51-0

Sequence : Gly-Glu-Pro-Pro-Pro-Gly- Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

MF : C62H98N16O22

MW : 1419.53552

Purity : 99%

Specification : 2mg/vial

Appearance : White Lyophilized Powder

Standard : USP

Certification : SGS

Method of Analysis : HPLC


 

Description


PC 157 has a strong anti-inflammatory activity in both acute and chronic inflammation models. In fact, preliminary results in clinical trials suggest that BPC 157 may become an important therapeutic tool for the treatment of inflammatory bowel disease. BPC 157 was shown to accelerate wound healing and to have a marked angiogenic effect.


In addition, it significantly facilitates the healing of bone fracture in rats. This peptide also exhibits an osteogenic effect significantly improving the healing of segmental bone defect. BPC 157 accelerates the healing of transected rat Achilles tendon and transected rat quadriceps muscle. 


FITC-phalloidin staining was able to demonstrate that BPC 157 induces F-actin formation in fibroblasts. Likewise, Western blot analysis was able to detect the production and activation of paxillin and FAK proteins. The western blot analysis also showed that BPC 157 increases the extent of phosphorylation of paxillin and FAK proteins without affecting the amounts produced.

 

Appliance


Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).


The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.


Application:


Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-saystem, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.

Keywords:BPC 157, intestinal anastomosis, short bowel, colocutaneous fistulas, inflammatory bowel disease, peptidergic agents, anastomosis, pentadecapeptide, antiulcer, clinical phase II


What are Peptides?


Peptides are biologically appearing short chains of amino acid monomers bridged by peptide (amide) bonds.


The covalent chemical bonds are constructed when the carboxyl family of one amino acid performs with the amine family of another. The shortest peptides are dipeptides, inculding 2 amino acids joined by a single peptide bond, followed by tripeptides, tetrapeptides, etc. Polypeptides are long, consistent, and unbranched peptide chains. Thus, peptides fall under the broad chemical series of biological oligomers and polymers, along with nucleic acids, oligosaccharides and polysaccharides, etc.


Peptides are diffrentiated from proteins on the basis of size, and as an arbitrary benchmark can be understood to have approximately 50 or fewer amino acids. Proteins consist of one or more polypeptides organized in a biologically functional way, often bound to ligands such as coenzymes and cofactors, or to another protein or other macromolecule (DNA, RNA, etc.), or to complicated macromolecular assemblies. Finally, while aspects of the lab techniques utilized to peptides versus polypeptides and proteins divers (e.g., the specifics of electrophoresis, chromatography, etc.), the size boundaries that distinguish peptides from polypeptides and proteins are not absolute: long peptides such as amyloid beta have been referred to as proteins, and smaller proteins like insulin have been regarded as peptides.


Amino acids that have been incorporated into peptides are called "residues" due to the release of either a hydrogen ion from the amine end or a hydroxyl ion from the carboxyl end, or both, as a water molecule is released during formation of each amide bond. All peptides except cyclic peptides have an N-terminal and C-terminal impurity at the end of the peptide (as shown for the tetrapeptide in the image).


Our Strengths:

 

1 High quality with competitive price: 


1) Standard: Enterprise Standard

2) All Purity≥98%

3) We are manufacturer and can provide high quality products with factory price. 

 

2 Fast and safe delivery:


1) Parcel can be sent out in 12 hours after payment. Tracking number available

2) Secure and discreet shipment. Various transportation methods for your choice. 

3) Customs pass rate ≥99%

4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring. 

 

3 We have clients throughout the world:


1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire. 

2) Market feedback and goods feedback will be appreciated, meeting customers' requirement is our responsibility. 

3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.


Any needs, please feel free to contact me.


Whatsapp:+8615308670259

Skype:+8615308670259


Send your message to this manufacturer
Email:
Message:
Your message must be between 20-8000 characters
 

© 2015 - 2024, wfdbn.com All rights reserved.